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Summary
Ovarian cancer is the eighth most commonly diagnosed cancer among women in the world, accounting for nearly  4% 
of all female cancers, also represent the third leading gynecologic cancer, and mortality is high because women typically 
present with late stage disease. Cases of suspected and confi rmed advanced stage ovarian cancer should be discussed by 
multidisciplinary team whitin which the pathologist is a key member.
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ULOGA PATOLOGA U DIJAGNOSTICI KARCINOMA JAJNIKA
Sažetak
Karcinoma jajnika je na osmom mjestu po učestalosti u žena u svijetu, čini gotovo 4% svih karcinoma u žena, također 
je na trećem mjestu unutar ginekoloških karcinoma a smrtnost je velika jer žene tipično dolaze u kasnom stadiju bolesti. 
Slučajevi sa suspektnim ili dokazanim uznapredovalim stadijem karcinoma jajnika moraju se raspraviti na multidisciplinar-
nom timu gdje je patolog ključan član tima. 
KLJUČNE RIJEČI: karcinom jajnika, patohistološka dijagnostika, prognostički čimbenici
INTRODUCTION
Ovarian cancer (OC) is the eighth most com-
monly diagnosed cancer among women in the 
world, accounting for nearly 4% of all female can-
cers (1). OC also represent the third leading gyne-
cologic cancer, and mortality is high because 
women typically present with late stage disease 
when the overall 5-year relative survival rate is 
44% (2). Despite the high incidence and mortality 
rates, the etiology of this lethal disease is not com-
pletely understood. Research to identify the causes 
of OC sorely needed; such knowledge could in-
form strategies for risk assessment, prevention, 
surveillance, early detection and treatment. Ovar-
ian cancer patients interact with many doctors 
during the course of their treatment, but rarely do 
they meet the specialist who plays a critical role in 
the outcome: the pathologist who diagnoses their 
cancer by analyzing samples of tissue. Precise di-
agnosis is what drives patient decisions and ther-
apy. If pathology is wrong, everything that fol-
lows will likely be incorrect as well. Cases of sus-
pected and confi rmed advanced stage ovarian 
cancer should be discussed by multidisciplinary 
team and pathologist is one the key person within 
the team. Never before in history have pathologist 
been so critically important.
CORE HISTOLOGICAL DATA
1. Tumor type
The tumor should be designated according to 
the World Health Organization (WHO) classifi ca-
tion (3). Epithelial ovarian tumors are heteroge-
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neous neoplasms which are primarily classifi ed 
according to cell type into serous, mucinous, en-
dometrioid, clear-cell, transitional and squamous 
cell tumors. More importantly, these tumors are 
further subdivided into benign, borderline (inter-
mediate), and malignant (carcinoma) depending 
on the degree of cell proliferation and nuclear 
atypia, and the presence or absence of stromal in-
vasion (4).
Borderline tumors show epithelial prolifera-
tion greater than that seen in their benign counter-
parts and variable nuclear atypia; however, in 
contrast to carcinomas, there is absence of stromal 
invasion, and their prognosis is much bett er than 
that of carcinomas. Despite the lack of stromal in-
vasion, serous borderline tumors, particularly 
those with exophytic gowth, can implant on peri-
toneal surfaces and, rarely progress to low-grade 
serous carcinoma (LGSC), and invade the under-
lying tissue. Mucinous borderline tumors should 
be subclassifi ed as intestinal ( more common) or 
endocervical (Mullerian) type.
Currently, based on histopathology, immu-
nohistochemikstry, and molecular genetic analy-
sis, at least fi ve main types of ovarian carcinomas 
are identifi ed: high-grade serous carcinomas 
(HGSC), endometrioid carcinoma ( EC), clear cell 
carcinomas (CCC), mucinous carcinomas (MC) 
and low-grade serous carcinomas (LGSC) (5).
2. Tumor grade
According to recent study serous carcinoma 
is low (LGSC) or high grade (HGSC). They are 
fundamentally diﬀ erent tumor types, and conse-
quently diﬀ erent diseases. LGSCs are associated 
in most cases with a serous borderline component, 
carry KRAS and BRAF mutations, and are unre-
lated to p53 mutatiolns and BRCA abnormalities. 
In contrast, HGSCs are not associated with serous 
borderline tumors and typically exhibit p53 muta-
tions and BRCA abnormalities (6).
Mucinous carcinoma are graded in a similar 
manner to endometrioid carcinoma, as is done in 
the uterus. Recently, mucinous carcinomas have 
been divided into two categories:an expansile 
type without obvious stromal invasion, but exibit-
ing back-to back or malignant glands with mini-
mal or no intervening stroma, and exceeding 10 
mm2 in area and an infi ltrative type showing evi-
dent stromal invasion. The expansile patt ern of 
growth is associated with a more favorable prog-
nosis than the infi ltrative patt ern (7).
Endometrioid carcinomas are graded as I,II 
or III using the FIGO grading system which is 
used for the grading of uterine endometrioid ad-
enocarcinomas (8).
Ovarian clear cell carcinomas and transition-
al cell carcinomas are regarded as automatically 
high grade or grade III.
3. Microinvasion
Microinvasion may occur within an other-
wise typical borderline tumor, usually of serous 
or mucinous type. Microinvasion has been found 
to have no adverse eﬀ ect on prognosis and may be 
multifocal. If the foci of microinvasion are clearly 
separate, these can be regarded as multiple dis-
tinct foci of microinvasion and the size of separate 
foci need not be added together (9).
4. Lymph nodes
The total number of lymph nodes examined 
from each anatomical site and the number in-
volved by tumor shoul be recorded.
5. Peritoneal biopsies
The presence or absence of tumor involve-
ment in biopsies from each anatomical site should 
be recorded. Peritoneal involvement in associa-
tion with an ovarian borderline tumor, especially 
of serous type, may take form of invasive or non-
invasive implants which may coexist. The lesions 
were confi ned to the surface of organs are non-in-
vasive implants or infi ltrated the underlying tis-
sue are invasive. This is a diﬃ  cult area and may 
require specialist internal or external review.
6. Omentum
The size of the largest omental metastatic de-
posit should be documented. Omental involve-
ment in association with a borderline tumor, espe-
cially of serous type, may take the form of invasive 
or non-invasive implants. Since invasive and non-
invasive implants may, on occasions, coexist and 
since invasive implants are associated with an ad-
verse prognosis are an indicator for adjuvant che-
motherapy, extensive omental sampling should 
be undertaken when non-invasive implants are 
identifi ed in the original sections.
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7. Fallopian tubes
The presence or abscence of tubal involve-
ment should be documented as well as site of tub-
al involvement, for example mucocal or serosal. 
Tubal involvement in ovarian carcinoma is not un-
common and the fi mbria is the most common site. 
It has, in fact been suggested that the tubal fi mbria 
is the site of origin of many pelvic serous carcino-
ma. It is now accepted that a number of what have 
been thought to be primary ovarian cancer are 
originated in other pelvic organs and involve the 
ovary secondarily (10).
8. Staging
Tumors should be staged according to the 
FIGO staging systems (11). Although it is useful to 
record the provisional stage on the histopathology 
report, the fi nal stage should be determined at the 
multidisciplinary team meeting (MDTM) where 
the results of all clinical, radiological and patho-
logical parameters can be correlated.
Some others parameters as the weight of the 
ovaries, the presene or absence of lymphovascular 
invasion, the results of any immunohistochemical 
studies may be included as part of a complete re-
port but their are of uncertain prognostic relevance.
The pathologist also needs key clinical infor-
mation, and the specimen request form should in-
clude full patient details and the results of any 
previous biopsy or cytology specimens.
Most ovarian carcinomas are removed with-
out a preoperative histological diagnosis, the diag-
nosis being made on the basis of a combination of 
clinical, serrological and radiological features in an 
MDTM sett ing. Sometimes radiologically guided 
core biopsies are performed to confi rm the diagno-
sis preoperatively or prior to chemotherapy or in 
patients who are too ill to undergo a laparotomy. 
The number of core biopsies should be stated and 
the length of each core documented. Tissue may 
need to be preserved so that a range of immunohis-
tochemical markers can be performed. Materials 
received with core biopsies are small biopsy speci-
mens and pathologists need to be highly qualifi ed 
and experienced in gynecological pathology. 
Intraoperative pathological consultation 
The frozen section is of value in cases where 
clinical management decisions may be altered de-
pending on the histological type and grade of tu-
mor, e.g. young women for whom continuing fer-
tility is crucial. 
Situations where frozen section examination 
might be performed include:
 – intraoperative assessment of a neoplasm con-
fi ned to the ovary to assess whether this is be-
nign, borderline or malignant; this may direct 
whether lymphadenectomy or other staging 
procedures are undertaken
 – for confi rmation of an epithelial neoplasm, for 
subtyping of an epithelial malignancy and, in 
cases of obvious malignancy to distinguish be-
tween a primary ovarian and a metastatic neo-
plasm.
Clinicians should be aware that a single sam-
ple may be not provide adequate material for the 
histopathologist whereas, further sampling for 
paraﬃ  n sections may result in upgrading of a fro-
zen section diagnosis of benign to borderline tu-
mor or of high grade borderline tumor to invasive 
carcinoma. If any doubt is expressed by the pa-
thologist in frozen section, the more conservative 
diagnosis must be the ‘working’ diagnosis for im-
mediate patient management (12).
The removed ovary with tumor mass should 
be ink because it is useful in easy identifi cation of 
capsular blocks and capsular integrity. Prior slic-
ing of the neoplasm may be undertaken to allow 
adequate fi xation. For suspected borderline tu-
mors the accepted standard is one block to tumor 
per centimetre of maximum diameter of the ‘solid’ 
ovarian mass. This is to detect small areas of high-
grade invasive carcinomas, which might other-
wise be missed, and is particularly important in 
mucinous tumors. Mucinous neoplasms may be 
extremely heterogeneous with close proximity of 
benign, borderline and malignant areas and more 
generous sampling may need to be undertaken, 
especially from grossly solid or suspicious areas, 
depending on the histological fi ndings in the orig-
inal sections (13). For cystic lesions with papillary 
processes on the internal or external surface, the 
papillary areas should be extensively blocked. If 
one of the ovaries  is grossly normal, one or two 
blocks will suﬃ  ce. In patient with BRCA 1 or 2 
mutations the entire ‘normal’ ovary should be 
submitt ed for histological examination.
Immunohistochemistry 
With many applications in the fi eld of ovari-
an neoplasia, the use of immunohistochemistry 
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has signifi cantly increased in recent years (14). 
The results of any immunohistochemical stains 
should always be carefully interpreted in conjunc-
tion with the clinical, gross and microscopic fea-
tures. However, areas where immunohistochem-
istry may contribute signifi cantly include the fol-
lowing:
 – distinction between a primary ovarian adenocar-
cinoma and metastatic adenocarcinoma from 
various sites ( potentially useful markers include 
cytokeratin 7 and 20, CA 125, CEA, CA 19.9, WT 
1, TTF-1, oestrogen receptor and CDX 2)
 – typing of an ovarian adenocarcinoma, most 
ovarian serous carcinoma exhibit nuclear posi-
tivity with WT 1, while most of the other mor-
phological subtypes are negative
 – the distinction between an epithelial and a sex 
cord-stromal tumor ( potential useful markers 
include inhibin, calretinin positive in sex cord-
stromal tumors and epithelial membrane anti-
gen- EMA and cytokeratin 7 positive in epithe-
lial neoplasms)
Molecular genetics
Many advances of molecular genetics of ova-
rian cancer have been made, but these are not yet 
aﬀ ecting clinical practice except BRCA 1 and 
BRCA 2 genes. Ovarian cancer mostly arises spo-
radically, but a fraction of cases are associated 
with mutation in BRCA 1 and BRCA 2 genes. The 
presence of BRCA mutations in ovarian cancer pa-
tients, especially in patients with HGSC has been 
suggested as a prognostic and predictive factor. 
Tumor pathological data are very important for 
the molecular analysis and should be included in 
the results of molecular testing (15).
CONCLUSION
Numerous studies in recent years have 
changed the classifi cation of epithelial ovarian tu-
mors especially due to the results of changes at the 
molecular level. Determination of prognostic and 
predictive factors, and interpretation of results of 
molecular testing requires higly experienced pa-
thologist in the fi eld of gynecological pathology. 
In addition, the pathologist has become a key per-
son in a multidisciplinary team and the person 
very responsible for the implementation of spe-
cifi c individual therapy.
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